Effectiveness, tolerability and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study.

Alicia Gonzalez-MartinezAncor Sanz-GarcíaDavid García-AzorínJaime Samuel Rodriguez-VicoAlex JaimesAndrea Gómez GarcíaJavier Casas LimónJavier Díaz de TeránMaría Sastre-RealJavier MembrillaGermán LatorreCarlos Calle de MiguelSendoa Gil LuqueCristina Trevino-PeinadoSonia QuintasPatricia HerediaAna Echavarría ÍñiguezÁngel Guerrero-PeralÁlvaro SierraNuria González-GarcíaJesús Porta-EtessamAna Beatriz Gago-Veiga

Published in: Pain medicine (Malden, Mass.) (2023)

Our study provides real world evidence of effectiveness and safety of anti-CGRP mAbs for migraine in patients without upper age-limit and possible predictors of anti-CGRP response in the elderly.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
systematic review
peritoneal dialysis
clinical trial
patient reported outcomes
patient reported
placebo controlled